Moreover, our experiments confirmed that the expression level of BCAT2 is regulated by AMPK-SREBP1 signaling pathway, which is supported by previous finding that genomic deletion of BCAT2 confers collateral lethality in pancreatic cancer [18]. The gene discussed is BCAT2; the disease is pancreatic neoplasm.